FLOT
Checked 2026-09-09
Resectable gastric or gastro-oesophageal junction adenocarcinoma, cT2 or higher or node-positive
One cycle
every 14 days × 4 · about 8 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Docetaxel Cytotoxic chemotherapy (taxane) | 50 mg/m² | IV | D1 | |
Oxaliplatin Third-generation platinum (DACH-platinum) | 85 mg/m² | IV | D1 | |
Leucovorin (folinic acid) | 200 mg/m² | IV | D1 | 2-hour infusion before fluorouracil |
Fluorouracil infusion Fluoropyrimidine antimetabolite | 2,600 mg/m² | IV | D1, 2 (24 h infusion) |
Cycles
4 before and 4 after surgery
14-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Consider (10-20% FN risk)
Notes
- MATTERHORN adds durvalumab 1,500 mg every 4 weeks to perioperative FLOT and continues it for 12 cycles.
Used in
Trials
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
mFOLFOX6
Adjuvant stage III colon (6 months) or metastatic colorectal and upper GI first line
every 14 days × 12
CAPOX
Adjuvant stage III colon (3 or 6 months), rectal total neoadjuvant therapy, metastatic first line
every 21 days × 4
FOLFIRI
Metastatic colorectal first or second line (with bevacizumab, aflibercept, ramucirumab or an anti-EGFR antibody)
every 14 days
CROSS chemoradiation
Resectable oesophageal or junctional cancer (T1N1 or T2-3N0-1), before surgery
weekly × 5
Nivolumab + FOLFOX or CAPOX
Unresectable or metastatic HER2-negative gastric, junctional or oesophageal adenocarcinoma, first line (benefit concentrated in PD-L1 CPS 5 or above)
every 14 days
Pembrolizumab + cisplatin + fluorouracil
Advanced oesophageal or Siewert type 1 junctional cancer, first line
every 21 days